We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04839601
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : November 14, 2022
Information provided by (Responsible Party):

Brief Summary:
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.

Condition or disease Intervention/treatment Phase
Epilepsy Partial Seizure Neurostimulator; Complications Drug Resistant Epilepsy Focal Epilepsy Device: RNS System Not Applicable

Detailed Description:

NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures. For the purposes of this study, disabling seizures are defined as motor partial seizures, complex partial seizures, and/or secondarily generalized seizures. The RNS System is currently approved by the FDA for use in patients 18 years and older with hard-to-treat partial-onset seizures. The same device will be used in the RESPONSE Study.

The study is a prospective open label single arm pivotal study and participants will be followed for 2 years after placement of the RNS System. The study will enroll a maximum of 200 subjects within the United States to ensure that at least 150 subjects are implanted with the RNS System.

The study design includes one interim analysis which will occur after the 75th implanted patient reaches 12 months post-implant. If the study achieves its primary safety and effectiveness endpoint goals at the interim analysis, the study will be considered successful and enrollment will be stopped.

If the interim analysis does not achieve the primary safety and effectiveness endpoint goals, the study will continue enrolling up to the maximum of 200 patients. A final analysis will be conducted after the 150th implanted patient reaches 12 months post-implant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RNS® System Responsive Stimulation for Adolescents With Epilepsy Study
Actual Study Start Date : October 27, 2021
Estimated Primary Completion Date : July 1, 2026
Estimated Study Completion Date : December 31, 2027

Arm Intervention/treatment
Experimental: Evaluation Group (stimulation ON)
Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
Device: RNS System
The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.

Primary Outcome Measures :
  1. Short-term chronic serious adverse device effect (SADE) rate [ Time Frame: 84-days post-implant ]
    The primary safety endpoint is the percent of subjects with serious device-related adverse events at 84 days (12 weeks) post-implant.

  2. Responder rate at 12 months post implant [ Time Frame: The primary effectiveness endpoint is the percent of subjects with a ≥ 50% reduction in seizures at 12 months post-implant compared to the pre-implant baseline. ]
    12 months post-implant

Other Outcome Measures:
  1. Device-related Serious Adverse Event (SADE) event rate [ Time Frame: Implant through 2 years post-implant ]
    The annual SADE event rate over time in subjects age 12 - 17 years implanted with the neurostimulator and/or leads during study participation will be calculated

  2. Event rate of Serious Adverse Events (SAEs) of particular relevance [ Time Frame: Implant through 2 years post-implant ]

    The annual event rate of SAEs of particular relevance (device-related or not) will be calculated over time in subjects age 12 - 17 years implanted with the neurostimulator and/or leads during study participation.

    SAEs of particular relevance include those related to:

    • infection
    • intracranial hemorrhage
    • new more disabling seizure types
    • suicidality

  3. Affective status as measured by the Beck Depression Inventory [ Time Frame: Implant through 2 years post-implant ]
    Affective status (by summary scores from the Beck Depression Inventory (BDI), either the BDI-II or Beck Youth Inventory (BYI-II), depending on age at time of the initial clinic appointment) will be described pre-implant, as well as for the post-implant months 3, 6, 9, 12 and then every four months.

  4. Neuropsychological functioning as assessed by a sub-set of tests in the NIH Toolbox Cognition Battery [ Time Frame: Implant through 2 years post-implant ]
    Neuropsychological functioning as assessed by neuropsychological testing with pediatric validated, standardized inventories to assess 3 domains that include attention, memory, and vocabulary (Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, respectively). These inventories are taken from the NIH Toolbox Cognition Battery and will be described by presenting summary scores for the pre-neurostimulator implant period, as well as for the annual appointments.

  5. Percentage change in seizure frequency [ Time Frame: Implant through 2 years post-implant ]
    The percentage change in seizure frequency will be summarized and reported by medians and responder rates for each 3-month interval beginning 4 months post-implant.

  6. Quality of life as assessed by the Quality of Life in Epilepsy Inventory (QOLIE) [ Time Frame: Implant through 2 years post-implant ]
    Quality of life [by summary scores from the QOLIE-AD-48 (validated for ages 12 - 17 years) or QOLIE-31-P (validated for ages 18 and older), depending on age at time of assessment] will be described pre-neurostimulator implant, as well as at yearly time points.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has disabling motor simple partial seizures, complex partial seizures, and/or secondarily generalized seizures. Disabling refers to seizures that are severe enough to cause injuries, or significantly impair functional ability in domains including employment, psychosocial education and mobility.
  • Subject has seizures that are distinct, stereotypical events that can be reliably counted, in the opinion of the investigator, by the subject or parent/caregiver.
  • Subject had an average of three or more disabling motor simple partial seizures, complex partial seizures and/or secondarily generalized seizures over the two most recent consecutive 30-day periods, with no 30-day period with less than two seizures per subject and/or parent/caregiver report.
  • Subject failed treatment with a minimum of two anti-seizure medications (used in appropriate doses) with adequate monitoring of compliance and the effects of treatment, as determined by the investigator.
  • Subject has undergone diagnostic testing as part of his/her standard care that has identified no more than two epileptogenic regions.
  • Subject is male or a female of childbearing potential using a reliable method of contraception (hormonal, barrier method, surgical or abstention).
  • Subject is age 12 or older but will be less than age 18 (has not reached 18th birthday) at the time of implantation with the RNS System.
  • Subject is able to maintain an electronic diary alone or with the assistance of a competent individual.
  • Subject is able to attend clinic appointments in accordance with the study schedule.
  • Subject and/or parent/guardian must be willing and able to provide informed consent and assent when appropriate.
  • Subject is not currently implanted with an RNS Neurostimulator or NeuroPace Leads.
  • In the investigator's opinion, subject is able to tolerate a neurosurgical procedure.

Exclusion Criteria:

  • Subject has been diagnosed with primarily generalized seizures.
  • Subject requires procedures that are contraindicated based on current RNS System labeling.
  • In the opinion of the investigator, the subject has a clinically significant or unstable medical condition (including alcohol and/or drug abuse) or a progressive central nervous system disease.
  • Subject has been diagnosed with active psychosis, major depression or suicidal ideation in the preceding year. Subjects with post-ictal psychiatric symptoms need not be excluded.
  • Subject is pregnant.
  • Subject is participating in a therapeutic investigational drug or other device study.
  • Subject is implanted with an electronic medical device that delivers electrical energy to the brain.
  • Subject has been diagnosed with psychogenic or non-epileptic seizures.
  • Subject has experienced unprovoked status epilepticus in the preceding year.
  • Subject is taking chronic anticoagulants.

Note: For contraindications, refer to current physician labeling (manuals) for the RNS System available at the NeuroPace website (www.neuropace.com).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04839601

Layout table for location contacts
Contact: Kerry Flynn 650-793-5277 kflynn@neuropace.com
Contact: Tracy Courtney tcourtney@neuropace.com

Layout table for location information
United States, California
Children's Health of Orange County Recruiting
Orange, California, United States, 92868
Contact: Angelyque Lorenzana    714-509-8972 ext 18972    Angelyque.Lorenzana@choc.org   
Principal Investigator: Joffre Olaya         
United States, Florida
Nicklaus Children's Hospital Recruiting
Miami, Florida, United States, 33155
Contact: Mari Vega       marinellie.vega@nicklaushealth.org   
Principal Investigator: Marytery Fajardo         
United States, Illinois
University of Chicago Withdrawn
Chicago, Illinois, United States, 60637
United States, Michigan
Spectrum Health System Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Jacquelyn Davis-Dudka       Jacquelyn.davis-dudka@spectrumhealth.org   
Principal Investigator: Anastasia Luniova, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Brian Lundstrom, MD, PhD         
United States, New York
Westchester Medical Center Recruiting
Hawthorne, New York, United States, 10532
Contact: Donika Zogejani    914-768-3970    dzogejan@nymc.edu   
Principal Investigator: Steve Wolf         
Cohen Children's Medical Center Withdrawn
Lake Success, New York, United States, 11042
Mount Sinai Hospital Withdrawn
New York, New York, United States, 10029
United States, Tennessee
Le Bonheur Children's Foundation Research Institute Withdrawn
Memphis, Tennessee, United States, 38105
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Martha Morrell, MD NeuroPace, Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: NeuroPace
ClinicalTrials.gov Identifier: NCT04839601    
Other Study ID Numbers: NP10014
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: November 14, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by NeuroPace:
Medically refractory
Responsive neurostimulation
Focal onset seizures
RNS System
Additional relevant MeSH terms:
Layout table for MeSH terms
Drug Resistant Epilepsy
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations